Sushil Patel
Förmögenhet: 14 M $ per 2026-09-30
Förmögenhet: 14 M $ per 2026-09-30
Sushil Patel is Chief Executive Officer & Director at Replimune Group, Inc. since 2024 and an Independent Director at Revolution Medicines, Inc. since 2022.
Formerly, Dr. Patel was Vice President-Franchise & Head-Oncology at Genentech, Inc. from 2018 to 2021.
Education includes an undergraduate degree from the University of Warwick in 1992, a graduate degree from Imperial College London in 1993, and a doctorate from the University of London in 1999.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
REPLIMUNE GROUP, INC. 0,75 % | 2026-08-10 | 708 151 ( 0,75 % ) | 9 M $ | 2026-09-30 |
| 2026-06-29 | 21 656 ( 0,01 % ) | 4 M $ | 2026-09-30 |
| Företag | Position | Start |
|---|---|---|
| REPLIMUNE GROUP, INC. | Verkställande Direktör | 2024-04-01 |
| REVOLUTION MEDICINES, INC. | Direktör/Styrelseledamot | 2022-06-16 |
| Företag | Position | Slut |
|---|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Företagsledare/Principal | 2021-05-01 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 6 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Imperial College London
Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of London
University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Warwick
University of Warwick Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Revolution Medicines, Inc.
Revolution Medicines, Inc. Pharmaceuticals: OtherHealth Technology Develops new therapies derived from natural products | Health Technology |
Replimune Group, Inc.
Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån